Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Rifaquizinone (Primary) ; Vancomycin
- Indications Bacterial infections; Gram-positive infections; Skin and soft tissue infections
- Focus Adverse reactions
- Acronyms P2_ABSSSI
- Sponsors TenNor Therapeutics
- 13 Sep 2023 Primary endpoints has been amended as Adverse Events endpoint has been removed and trial focus has now shifted to only Tu.
- 13 Jan 2022 Primary endpoints has been amended as Early Clinical Response endpoint has been added and trial focus has now shifted to Tu and Ar.
- 25 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Jun 2020.